Early mortality (mortality up to 90 days) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early mortality (mortality up to 90 days) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early mortality (mortality up to 90 days) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether chlorpromazine changes leaving the study early: for any reason compared with clotiapine (very low certainty).
1 finding from 1 review
Intervention not reported
Leaving the study early: any reason (medium term) · patients with schizophrenia
The intervention showed no clear difference in leaving the study early: any reason (medium term) (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · women in labour with planned vaginal delivery
1 finding from 1 review
Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · women in labour with planned vaginal delivery
1 finding from 1 review
Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · women in labour with planned vaginal delivery
1 finding from 1 review
Reduction in pain intensity · women in labour with planned vaginal delivery
1 finding from 1 review
Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · women in labour with planned vaginal delivery
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
YOGA probably leads to lower leaving the study early: short term compared with NON‐STANDARD CARE (moderate certainty).
1 finding from 1 review
Leaving the study early Leaving the study early: participants lost to · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Early mortality (90 days) · patients with diffuse emphysema
The intervention probably leads to higher early mortality (90 days) (moderate certainty).
1 finding from 1 review
Early initiation of breastfeeding · women exposed to interventions intended to promote breastfeeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early initiation of breastfeeding · women exposed to interventions intended to promote breastfeeding
It is very uncertain whether non‐healthcare professional‐led breastfeeding education and support changes early initiation of breastfeeding compared with standard care (very low certainty).
1 finding from 1 review
Intervention not reported
Miscarriage rate ‐ Early versus late clomiphene citrate · ovulation induction in polycystic ovarian syndrome
It is very uncertain whether the intervention changes miscarriage rate ‐ Early versus late clomiphene citrate (very low certainty).
1 finding from 1 review
Intervention not reported
Clinical pregnancy ‐ Early versus late clomiphene citrate · ovulation induction in polycystic ovarian syndrome
The intervention may leads to higher clinical pregnancy ‐ Early versus late clomiphene citrate (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in leaving the study early: Overall tolerability Leaving the study… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review